ATE355103T1 - Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür - Google Patents

Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür

Info

Publication number
ATE355103T1
ATE355103T1 AT04813471T AT04813471T ATE355103T1 AT E355103 T1 ATE355103 T1 AT E355103T1 AT 04813471 T AT04813471 T AT 04813471T AT 04813471 T AT04813471 T AT 04813471T AT E355103 T1 ATE355103 T1 AT E355103T1
Authority
AT
Austria
Prior art keywords
dosage form
active ingredient
production method
adverse agent
extruded
Prior art date
Application number
AT04813471T
Other languages
German (de)
English (en)
Inventor
Robert P Flath
John K Masselink
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE355103T1 publication Critical patent/ATE355103T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04813471T 2003-12-09 2004-12-08 Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür ATE355103T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52855003P 2003-12-09 2003-12-09

Publications (1)

Publication Number Publication Date
ATE355103T1 true ATE355103T1 (de) 2006-03-15

Family

ID=34676850

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04813471T ATE355103T1 (de) 2003-12-09 2004-12-08 Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür

Country Status (13)

Country Link
US (1) US20070269505A1 (https=)
EP (1) EP1691892B1 (https=)
JP (3) JP4917893B2 (https=)
AT (1) ATE355103T1 (https=)
CA (1) CA2548834C (https=)
CY (1) CY1106600T1 (https=)
DE (1) DE602004005076T2 (https=)
DK (1) DK1691892T3 (https=)
ES (1) ES2281851T3 (https=)
PL (1) PL1691892T3 (https=)
PT (1) PT1691892E (https=)
SI (1) SI1691892T1 (https=)
WO (1) WO2005055981A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
MXPA05011071A (es) 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ES2281851T3 (es) * 2003-12-09 2007-10-01 Euro-Celtique S.A. Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
KR100963914B1 (ko) 2004-03-30 2010-06-17 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
SI2719378T1 (sl) * 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2224806A4 (en) * 2007-12-17 2014-02-19 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20110262407A1 (en) * 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
ES2414856T3 (es) 2008-12-12 2013-07-23 Paladin Labs Inc. Formulaciones de fármaco narcótico con potencial de adicción disminuido
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
BRPI1001091A2 (pt) * 2009-04-22 2011-03-22 Dr Suwelack Skin & Health Care Ag artigo moldado revestido secado por congelamento
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ITVR20110069A1 (it) * 2011-04-06 2012-10-07 Eurocoating S P A Metodo per la realizzazione di un biomateriale a base di calcio fosfato sotto forma di granuli e/o loro aggregati e biomateriale ottenuto con lo stesso
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
EP2755638B1 (en) * 2011-09-16 2016-06-01 Purdue Pharma LP Tamper resistant immediate release formulations
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP2835246A1 (en) * 2013-08-05 2015-02-11 Ansa Termoplastici S.r.l. Method and apparatus for producing extruded plastic elements
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
IN183097B (https=) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
CN1703200B (zh) * 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
MXPA05011071A (es) * 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
ES2281851T3 (es) * 2003-12-09 2007-10-01 Euro-Celtique S.A. Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.

Also Published As

Publication number Publication date
JP4917893B2 (ja) 2012-04-18
JP2012082214A (ja) 2012-04-26
JP5473958B2 (ja) 2014-04-16
PT1691892E (pt) 2007-05-31
DK1691892T3 (da) 2007-06-25
EP1691892B1 (en) 2007-02-28
WO2005055981A2 (en) 2005-06-23
US20070269505A1 (en) 2007-11-22
ES2281851T3 (es) 2007-10-01
WO2005055981A3 (en) 2005-08-11
EP1691892A2 (en) 2006-08-23
JP2007513960A (ja) 2007-05-31
CA2548834C (en) 2009-08-11
CA2548834A1 (en) 2005-06-23
DE602004005076T2 (de) 2007-11-15
PL1691892T3 (pl) 2007-07-31
DE602004005076D1 (de) 2007-04-12
SI1691892T1 (sl) 2007-08-31
JP2011126895A (ja) 2011-06-30
CY1106600T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE355103T1 (de) Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
ATE419836T1 (de) Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
WO2004093819A3 (en) Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
WO2005107726A3 (en) Method for the treatment of back pain
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
DE60328128D1 (de) Verfahren zur schmerzbehandlung durch verabreichung eines antagonistischen antikörpers gegen den nervenwachstumfaktor und eines opioid-analgetikums sowie diese enthaltende zusammensetzungen
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
Summey Jr et al. Pharmacologic advances in the systemic treatment of itch
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
MX2009010854A (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
WO2004016256A3 (en) AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
DE60236496D1 (de) Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
TW200507840A (en) Method of treating multiple myeloma
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
Janowsky et al. Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: A potential nerve agent treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1691892

Country of ref document: EP